Mo1805 Untargeted Metabolomics Reveals Disruption Within Bile Acid, Cholesterol, and Tryptophan Metabolic Pathways in Dogs With Idiopathic Inflammatory Bowel Disease

Honneffer, Julia B.; Guard, Blake C.; Steiner, Jöerg M.; Suchodolski, Jan S.

doi:10.1016/s0016-5085(15)32435-5

Cited by 23 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, clear differences were observed in the fecal metabolome between the two treatment strategies. Measuring fecal metabolites allows assessment of functional changes in the intestinal microbiota, but also assessment of abnormalities in host-derived metabolites (24,41). Therefore, bacterial-derived metabolites would be expected to correlate with improvement or worsening of microbial dysbiosis.…”

Section: Discussionmentioning

confidence: 99%

Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole

Chaitman¹,

Ziese²,

Pilla

et al. 2020

Front. Vet. Sci.

Self Cite

119

View full text Add to dashboard Cite

The aim was to characterize differences in fecal consistency, and fecal microbiota and metabolome profiles in dogs with acute diarrhea (AD) treated with either fecal microbiota transplantation as enema (FMT; n = 11) or oral metronidazole (MET; n = 7) for 7 days. On days 0, 7, and 28 fecal samples were obtained. Fecal samples from healthy dogs (HC; n = 14) were used for comparison. Samples were analyzed by the previously validated qPCR based canine Dysbiosis Index (DI; increased values indicate microbiota dysbiosis) and 16S rRNA gene sequencing. The fecal metabolome was analyzed using a previously validated targeted canine assay for fecal unconjugated bile acids, and untargeted metabolomics. Fecal consistency improved significantly in dogs treated with FMT and MET by day 7 and day 28 (p < 0.01) compared to day 0. However, on day 28 fecal consistency was significantly better in FMT compared to MET (p = 0.040). At day 0, dogs with AD had an altered microbiota indicated by significantly increased DI, decreased alpha-diversity, and altered beta-diversity. In the FMT group, the DI decreased over time, while MET led to a significant increase in the dysbiosis index at day 7 and 28 compared to FMT. Sequencing data revealed that in FMT microbial diversity and beta-diversity was similar to HC at day 28, while in MET these parameters were still significantly different from HC. In dogs treated with FMT, a decrease in cholic acid and the percentage of primary bile acids was observed, whereas treatment with metronidazole led to an increase in cholic acid at day 7 and an increase in percentage of primary bile acids over time. Based on untargeted metabolomics, dogs with AD had an altered fecal metabolome compared to HC. Dogs treated with FMT clustered closer to HC at day 28, while dogs treated with MET did not. In this pilot study, dogs with AD had significant differences in fecal microbiota and metabolome profiles. Dogs treated with MET still had altered microbial and metabolic profiles at day 28 compared to dogs treated with FMT or healthy dogs.

show abstract

Section: Discussionmentioning

confidence: 99%

Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole

Chaitman¹,

Ziese²,

Pilla

et al. 2020

Front. Vet. Sci.

Self Cite

119

View full text Add to dashboard Cite

show abstract

“…Tryptophan was the only amino acid found to be decreased in serum from dogs with protein-losing enteropathy, a form of chronic enteropathy, and lower serum tryptophan was correlated to lower serum albumin and poorer outcomes (92). In addition, in dogs with IBD, several indole compounds were found to be significantly decreased in fecal samples (93).…”

Section: Gut Microbiome and Gi Diseasesmentioning

confidence: 95%

The Role of the Canine Gut Microbiome and Metabolome in Health and Gastrointestinal Disease

2020

Self Cite

View full text Add to dashboard Cite

“…These patients exhibit increased fecal concentrations of primary bile acids and decreased concentrations of secondary bile acids, and clinical signs are often managed by use of bile acid sequestrants (eg, cholestyramine) . An untargeted metabolomics approach identified select altered fecal bile acids in dogs with IBD . Despite the growing body of information describing altered fecal bile acids in humans with chronic GI disease, fecal bile acids in dogs with CE that undergo treatment have not yet been reported.…”

Section: Introductionmentioning

confidence: 99%

“…[13][14][15][16] An untargeted metabolomics approach identified select altered fecal bile acids in dogs with IBD. 17 Despite the growing body of information describing altered fecal bile acids in humans with chronic GI disease, fecal bile acids in dogs with CE that undergo treatment have not yet been reported.…”

mentioning

confidence: 99%

Longitudinal assessment of microbial dysbiosis, fecal unconjugated bile acid concentrations, and disease activity in dogs with steroid‐responsive chronic inflammatory enteropathy

Guard

Honneffer

Jergens

et al. 2019

Veterinary Internal Medicne

Self Cite

View full text Add to dashboard Cite

Background Mounting evidence from human studies suggests that bile acid dysmetabolism might play a role in various human chronic gastrointestinal diseases. It is unknown whether fecal bile acid dysmetabolism occurs in dogs with chronic inflammatory enteropathy (CE). Objective To assess microbial dysbiosis, fecal unconjugated bile acids (fUBA), and disease activity in dogs with steroid‐responsive CE. Animals Twenty‐four healthy control dogs and 23 dogs with steroid‐responsive CE. Methods In this retrospective study, fUBA were measured and analyzed. Fecal microbiota were assessed using a dysbiosis index. The canine inflammatory bowel disease activity index was used to evaluate remission of clinical signs. This was a multi‐institutional study where dogs with steroid‐responsive CE were evaluated over time. Results The dysbiosis index was increased in dogs with CE (median, 2.5; range, −6.2 to 6.5) at baseline compared with healthy dogs (median, −4.5; range, −6.5 to −2.6; P = .002) but did not change in dogs with CE over time. Secondary fUBA were decreased in dogs with CE (median, 29%; range, 1%‐99%) compared with healthy dogs (median, 88%; 4%‐96%; P = .049). The percent of secondary fUBA in dogs with CE increased from baseline values (median, 28%; range, 1%‐99%) after 2‐3 months of treatment (median, 94%; range, 1%‐99%; P = 0.0183). Conclusions and Clinical Importance These findings suggest that corticosteroids regulate fecal bile acids in dogs with CE. Additionally, resolution of clinical activity index in dogs with therapeutically managed CE and bile acid dysmetabolism are likely correlated. However, subclinical disease (i.e., microbial dysbiosis) can persist in dogs with steroid‐responsive CE.

show abstract

Mo1805 Untargeted Metabolomics Reveals Disruption Within Bile Acid, Cholesterol, and Tryptophan Metabolic Pathways in Dogs With Idiopathic Inflammatory Bowel Disease

Cited by 23 publications

References 0 publications

Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole

Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole

The Role of the Canine Gut Microbiome and Metabolome in Health and Gastrointestinal Disease

Longitudinal assessment of microbial dysbiosis, fecal unconjugated bile acid concentrations, and disease activity in dogs with steroid‐responsive chronic inflammatory enteropathy

Contact Info

Product

Resources

About